MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
30.11
+1.29
+4.48%
Opening 11:13 03/28 EDT
OPEN
29.99
PREV CLOSE
28.82
HIGH
31.00
LOW
29.88
VOLUME
32.83K
TURNOVER
0
52 WEEK HIGH
31.00
52 WEEK LOW
4.000
MARKET CAP
453.57M
P/E (TTM)
-4.8758
1D
5D
1M
3M
1Y
5Y
Jasper Therapeutics Initiated at Outperform by RBC Capital
Dow Jones · 6h ago
Jasper Therapeutics Price Target Announced at $70.00/Share by RBC Capital
Dow Jones · 6h ago
RBC Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $70
Benzinga · 6h ago
Weekly Report: what happened at JSPR last week (0318-0322)?
Weekly Report · 3d ago
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Jasper Therapeutics, Inc. Management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28, 2024. Jasper is a biotechnology company focused on development of briquilimab, a novel antibody therapy.
Barchart · 03/21 15:30
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
TipRanks · 03/20 13:05
Analysts’ Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
TipRanks · 03/20 13:00
Jasper Therapeutics Announces First Patient Dosed In Phase 1b/2a SPOTLIGHT Clinical Study Of Briquilimab In Chronic Inducible Urticaria
First patient has been dosed in Jasper's Phase 1b/2a clinical study of briquilimab for the treatment of chronic spontaneous urticaria. Jasper is focused on development of a novel antibody therapy targeting c-Kit in mast cell driven diseases. The company anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024.
Benzinga · 03/19 12:05
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.